Skip to main content
. 2019 Jul 17;10:796. doi: 10.3389/fphar.2019.00796

Figure 7.

Figure 7

Effects of BSYS-containing serum and the inhibitors LY294002, U0126, and U73122 on cell viability, GAP-43, and CREB protein expression and neurite outgrowth in SH-SY5Y cells. SH-SY5Y cells were seeded in low-serum medium (0.25% FBS) for 24 h and then treated with medicine-free serum or serum containing medicines from BSYS for 24 h prior to exposure to the inhibitors LY294002 (60 µmol/L), U0126 (10 µmol/L), and U73122 (0.5 µmol/L) for 1 h. (A) Cell viability was determined by a CCK-8 assay, as described in the Materials and Methods, and expressed as a percentage relative to the control. (B and C) Neurite length, neurite-bearing cells, and the expression of β-tubulin-III were determined by an immunofluorescence (IF) assay (400×), as described in the Materials and Methods. (D) GAP-43 and p-CREB/CREB protein expression was detected by WB, as described in the Materials and Methods. Data represent the mean ± SE. n = 6. *P < 0.05, **P < 0.01, ***P < 0.001 vs. NC; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. MO; △ P < 0.05, △△ P < 0.01, △△△ P < 0.001 vs. BSYS; ▲ P < 0.05, ▲▲ P < 0.01, vs. LY294002 + BSYS.